Junshi Biotech (688180.SH) released its report for the first quarter of 2024, with revenue of 381 million yuan, an increase of 49.24% over the previous year. Net loss attributable to shareholders of listed companies was 283 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of $307 million. Basic earnings per share - $0.29.
君实生物(688180.SH)发一季度业绩,净亏损2.83亿元
Junshi Biotech (688180.SH) reported first-quarter results with a net loss of 283 million yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.